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Research
Polyfluoroalkyl chemicals (PFCs) are a class of 
highly stable compounds used widely in com-
mercial and industrial applications as surfactants, 
paper and textile coatings, and food packag-
ing (Calafat et al. 2007). Numerous chemi-
cals belong to this class, including the products 
used industrially, by-products of manufacturing, 
and degradation products. They are composed 
of a fluorinated carbon backbone of varying 
length terminated by a carboxylate or sulfonate 
functional group. This amphipathic structure 
provides the properties of water and oil repel-
lency and stain resistance (Conder et al. 2008). 
The perfluorinated carboxylates include perfluo-
rooctanoic acid (PFOA) and perfluorononanoic 
acid (PFNA), and the perfluorinated sulfonates 
include perfluorooctane sulfonic acid (PFOS) 
and perfluorohexane sulfonic acid (PFHxS). 
Biomonitoring studies have documented 
human exposure to PFCs, both in occupation-
ally exposed cohorts (Costa et al. 2009; Olsen 
and Zobel 2007; Sakr et al. 2007a) and in 
the general population (Apelberg et al. 2007; 
Calafat et al. 2007; Fei et al. 2007). Although 
the major sources of human exposure are 
poorly known, possibilities include diet (either 
directly from food or migration from food 
packaging), drinking water, and house dust 
(reviewed in Lau et al. 2007).
Once taken into the human body, PFCs 
are slowly eliminated and are not known to 
undergo biotransformation (Lau et al. 2007). 
They bioaccumulate, but not in lipid as do 
many other persistent organic pollutants. 
Instead, they bind to proteins in the liver 
and serum (Conder et al. 2008). Mean serum 
half-lives in humans are estimated as 5.4 years 
for PFOS and 3.8 years for PFOA (Olsen 
et al. 2007). Shorter-chain compounds are 
generally assumed to have shorter half-lives, 
although PFHxS is an exception, with an esti-
mated mean half-life of 8.5 years (Olsen et al. 
2007). The half-life for PFNA in humans has 
not been estimated.
Various adverse health effects have been 
observed in animal studies of PFOS and 
PFOA, including tumors in certain organs 
and developmental delays (Biegel et al. 2001; 
White et al. 2007). The structural resemblance 
of PFCs to fatty acids and the discovery that 
they bind to peroxisome proliferator-activated 
receptors (PPARs), nuclear receptors that play 
a key role in lipid metabolism and adipogen-
esis, have raised the concern that PFCs may 
disrupt lipid and weight regulation. Indeed, 
among the early reported health effects in 
animal studies that administered high PFC 
doses was hypolipidemia (Seacat et al. 2002). 
However, several studies in humans sug-
gest that exposure to PFOA, and possibly 
to PFOS, may be associated with increased 
cholesterol in humans (C8 Science Panel 
2008; Costa et al. 2009; Sakr et al. 2007a). 
The evidence for an association between PFC 
exposure and body size and insulin resistance 
is much weaker (Lin et al. 2009).
The rising prevalence of the metabolic 
syndrome, which includes obesity, dyslipi-
demia, and insulin resistance, is of increas-
ing public health concern in the United 
States and globally and is linked closely with 
coronary heart disease and related disorders 
(Ramos and Olden 2008). Although changes 
in diet and lifestyle are undoubtedly impor-
tant factors in this trend, there is growing 
interest in the hypothesis that endocrine-
disrupting chemicals may be playing a role 
(Grun and Blumberg 2009). 
This exploratory, cross-sectional epide-
miologic study investigated the relationship 
between exposure to four PFCs, including 
two compounds that have been little studied 
in humans, and cholesterol levels, obesity, 
and insulin resistance. 
Materials and Methods
Study population. The National Health and 
Nutrition Examination Survey (NHANES) is 
an ongoing survey of the civilian noninstitu-
tionalized U.S. population conducted by the 
Centers for Disease Control and Prevention 
(CDC) that gathers data on dietary and health 
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ba c K g r O u n D: Polyfluoroalkyl chemicals (PFCs) are used commonly in commercial applications 
and are detected in humans and the environment worldwide. Concern has been raised that they 
may disrupt lipid and weight regulation. 
Objectives: We investigated the relationship between PFC serum concentrations and lipid and 
weight outcomes in a large publicly available data set. 
Me t h O D s : We analyzed data from the 2003–2004 National Health and Nutrition Examination 
Survey (NHANES) for participants 12–80 years of age. Using linear regression to control for covari-
ates, we studied the association between serum concentrations of perfluorooctanoic acid (PFOA), 
perfluorononanoic acid (PFNA), perfluorooctane sulfonic acid (PFOS), and perfluorohexane sulfo-
nic acid (PFHxS) and measures of cholesterol, body size, and insulin resistance. 
re s u l t s: We observed a positive association between concentrations of PFOS, PFOA, and PFNA 
and total and non-high-density cholesterol. We found the opposite for PFHxS. Those in the highest 
quartile of PFOS exposure had total cholesterol levels 13.4 mg/dL [95% confidence interval (CI), 
3.8–23.0] higher than those in the lowest quartile. For PFOA, PFNA, and PFHxS, effect estimates 
were 9.8 (95% CI, –0.2 to 19.7), 13.9 (95% CI, 1.9–25.9), and –7.0 (95% CI, –13.2 to –0.8), 
respectively. A similar pattern emerged when exposures were modeled continuously. We saw little 
evidence of a consistent association with body size or insulin resistance.
cO n c l u s i O n s: This exploratory cross-sectional study is consistent with other epidemiologic stud-
ies in finding a positive association between PFOS and PFOA and cholesterol, despite much lower 
exposures in NHANES. Results for PFNA and PFHxS are novel, emphasizing the need to study 
PFCs other than PFOS and PFOA.
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fonic acid, perfluorooctanoic acid, polyfluoroalkyl chemicals, waist circumference. Environ Health 
Perspect 118:197–202 (2010).  doi:10.1289/ehp.0901165 available via http://dx.doi.org/ [Online 
2 November 2009]Nelson et al.
198  v o l u m e  118 | n u m b e r 2 | February 2010  •  Environmental Health Perspectives
factors. Participants are selected using a com-
plex multistage probability sampling design 
and come to a mobile examination center for 
a physical examination and to provide blood 
and urine samples. Various questionnaires are 
administered by trained interviewers (CDC 
2009). The survey also includes biomonitor-
ing for different environmental chemicals, 
including PFCs, of a random one-third 
subsample of participants by the National 
Center for Environmental Health (NCEH). 
NHANES obtained informed consent from 
all participants. 
PFC concentrations. PFCs were mea-
sured in serum of participants ≥ 12 years of 
age by the NCEH using automated solid-
phase extraction coupled to isotope dilution/
high-performance liquid chromatography/
tandem mass spectrometry; details of labora-
tory methods are available elsewhere (Calafat 
et al. 2007). Our study examined the four 
PFCs detected in > 98% of people: PFOS, 
PFOA, PFHxS, and PFNA. The other eight 
PFCs measured were detected in < 28% of 
people. Values below the limit of detection 
(LOD) were reported by NHANES as the 
LOD divided by the square root of 2. 
Outcomes. Several cholesterol measures are 
commonly used in clinical and epidemiologic 
studies. Cholesterol is carried in plasma within 
different lipoproteins, including low-density 
lipoproteins (LDLs) and very low-density lipo-
proteins (VLDLs) which carry cholesterol to 
peripheral tissues and are considered “bad” 
cholesterol, and high-density lipoproteins 
(HDLs) which transport cholesterol back 
to the liver for excretion and are considered 
“good” cholesterol. LDL carries around 70% 
of total plasma cholesterol, and HDL 20–30% 
(Tietz et al. 2006). Total cholesterol (TC) is 
the sum of the cholesterol content of LDL, 
HDL, and VLDL. The non-HDL cholesterol 
fraction, which includes LDL and VLDL cho-
lesterol, has been shown to be a better predic-
tor of risk of coronary heart disease than LDL 
alone (Liu et al. 2006).
We studied TC, HDL, non-HDL, and 
LDL. TC and HDL were measured by 
NHANES directly in serum of all participants; 
TC was measured enzymatically through cou-
pled reactions that hydrolyze cholesteryl esters, 
and HDL after the precipitation of apolipo-
protein B lipoproteins with a blocking agent 
(CDC 2007b). We calculated non-HDL by 
subtracting HDL from TC. LDL was avail-
able only for the subsample of fasting partici-
pants and was not measured directly in serum, 
but estimated by NHANES using the widely 
accepted Friedewald formula (CDC 2007c). 
Body size outcomes considered include 
body mass index (BMI): weight (kilograms) 
divided by height (meters squared), and waist 
circumference (WC; centimeters). Weight, 
height, and WC were measured during the 
examination using standard protocols (CDC 
2007d). To assess insulin resistance, we stud-
ied homeostatic model assessment (HOMA), 
used in epidemiologic studies as a simple, 
inexpensive, and reliable alternative to more 
complicated methods (Bonora et al. 2000). 
We calculated HOMA using the method of 
Matthews et al. (1985): HOMA = [fasting 
insulin (µU/mL) × fasting glucose (mmol/
L)]/22.5. Plasma insulin and glucose were mea-
sured enzymatically by NHANES in the fasting 
subsample of participants (CDC 2007a).
Covariates. NHANES collected data 
on potential confounding variables through 
questionnaires. Because we had a large sample 
size, our models included a priori a number of 
covariates that are important predictors of cho-
lesterol and body weight: age, sex, race/ethnic-
ity, socioeconomic status (SES, a dichotomous 
indicator that combined income, education, 
and food insecurity to minimize missing data), 
saturated fat intake (tertiles, as percentage of 
total caloric intake), exercise (performed mod-
erate or vigorous physical activity in the pre-
ceding 30 days), and time in front of a TV 
or computer (categories of hours per day in 
the preceding 30 days). For those ≥ 20 years 
of age, we also included alcohol consumption 
(categories of drinks per week), smoking, and, 
for women, parity. For the cholesterol analy-
ses, we included continuous BMI as a covari-
ate, and tested for confounding by continuous 
serum albumin. See Supplemental Material, 
Table 1, available online (doi:10.1289/
ehp.0901165.S1 via http://dx.doi.org/) for 
details on covariates.
Statistical analysis. We performed regres-
sion analyses in sex and age (12–19, 20–59, 
60–80 years) subgroups for each PFC sepa-
rately. When results showed similar trends by 
age and sex, we combined groups. Cholesterol 
and weight outcomes were analyzed as con-
tinuous variables; HOMA was log-trans-
formed as it was log-normally distributed. 
For the main analysis, exposure was mod-
eled in quartiles of PFC concentration, with 
Table 1. Distribution of cholesterol outcomes and PFC concentrations, persons 20–80 years of age.
No. Median Mean ± SD Range
TC (mg/dL) 860 199.0 202.1 ± 42.3 86–394
HDL (mg/dL) 860 53.0 54.6 ± 15.4 23–122
Non-HDL (mg/dL) 860 143.0 147.5 ± 43.4 52–361
LDL (mg/dL) 416 115.0 117.1 ± 35.6 21–252
PFOA (µg/L) 860 3.9 4.6 ± 3.0 0.1–37.3
Quartile 1 223 2.1 1.9 ± 0.6 0.1–2.7
Quartile 2 211 3.4 3.4 ± 0.4 2.8–3.9
Quartile 3 186 4.6 4.6 ± 0.4 4.0–5.4
Quartile 4 240 6.9 8.0 ± 3.3 5.5–37.3
PFOS (µg/L) 860 21.0 25.3 ± 20.6 1.4–392.0
Quartile 1 193 9.9 9.6 ± 2.9 1.4–13.6
Quartile 2 198 17.3 17.0 ± 1.8 13.8–19.7
Quartile 3 211 23.5 23.6 ± 2.4 19.8–28.1
Quartile 4 258 37.5 44.8 ± 28.0 28.2–392.0
PFNA (µg/L) 860 1.0 1.3 ± 1.2 0.1–10.3
Quartile 1 170 0.4 0.4 ± 0.1 0.1–0.5
Quartile 2 183 0.7 0.7 ± 0.1 0.6–0.8
Quartile 3 246 1.0 1.1 ± 0.1 0.9–1.3
Quartile 4 261 2.0 2.5 ± 1.5 1.4–10.3
PFHxS (µg/L) 860 1.8 2.6 ± 2.7 0.2–27.1
Quartile 1 217 0.8 0.7 ± 0.3 0.2–1.1
Quartile 2 239 1.5 1.5 ± 0.2 1.2–1.9
Quartile 3 233 2.4 2.6 ± 0.5 2.0–3.5
Quartile 4 171 5.3 6.7 ± 3.7 3.6–27.1
This table presents data for the population analyzed in Figure 1 and Table 2: 20- to 80-year-olds with full information 
on outcomes, exposures, and covariates. Quartiles of PFC exposure were calculated in the overall population (which 
included 12- to 19-year-olds and people missing covariate information). Therefore, the number of people in each PFC 
quartile is unequal. 
Table 2. Change in cholesterol measure (milligrams per deciliter) per microgram per liter increase in PFC, 
persons 20–80 years of age.
TC coefficient 
(95% CI)
HDL coefficient 
(95% CI)
Non-HDL coefficient 
(95% CI)
LDL coefficient 
(95% CI)
PFOS 0.27 (0.05 to 0.48) 0.02 (–0.05 to 0.09) 0.25 (0 to 0.50) 0.12 (–0.17 to 0.41)
PFOA 1.22 (0.04 to 2.40) –0.12 (–0.41 to 0.16) 1.38 (0.12 to 2.65) –0.21 (–1.91 to 1.49)
PFNA 2.01 (–1.16 to 5.18) –0.40 (–0.90 to 0.09) 2.56 (–1.19 to 6.30) 0.50 (–3.94 to 4.93)
PFHxS –0.93 (–1.80 to –0.06) 0.19 (–0.18 to 0.55) –1.13 (–1.90 to –0.35) –2.06 (–3.54 to –0.58)
All models are adjusted for age, sex, race/ethnicity, SES, saturated fat intake, exercise, time in front of a TV or com-
puter, BMI, alcohol consumption, and smoking. We excluded values identified as influential points and outliers from the 
population of adults (n = 860) in Table 1 and Figure 1. Most analyses excluded one or two points except PFNA and TC (4), 
PFNA and HDL (6), PFNA and non-HDL (4), PFHxS and non-HDL (0), and PFHxs and LDL (5). See Supplemental Material, 
Table 4 (doi:10.1289/ehp.0901165.S1), for a full listing of the number of outliers excluded in each analysis.PFCs and cholesterol in the general U.S. population
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quartiles formed in the population overall and 
separately for the age/sex group used in the 
analysis. We present effect estimates for each 
quartile compared with the reference group 
(the first quartile) and their corresponding 
95% confidence intervals (CIs). Tests for 
trend in the quartile analyses were performed 
by treating PFC category as a linear predictor 
in the models. 
In addition, for cholesterol outcomes in 
adults, we performed a sensitivity analysis that 
modeled exposure as a continuous predictor. 
We identified influential points and outliers 
by examining studentized residuals, predicted 
values, and scatter plots, and excluded them 
from the analysis if they changed the effect 
estimates by ≥ 5%. 
All analyses excluded those > 80 years of 
age, pregnant, breast-feeding, taking insu-
lin, or undergoing dialysis. Cholesterol 
analyses also excluded those who reported 
current use of cholesterol-lowering medica-
tions in the blood pressure portion of the 
questionnaire or who were missing this vari-
able. See Supplemental Material, Figure 1 
(doi:10.1289/ehp.0901165.S1), for the 
number of people in each exclusion group. 
Covariates described above were used in all 
models for which they were available, depend-
ing on age group and sex.
To perform analyses, we used the SAS ver-
sion 9.1 Proc SURVEYREG (SAS Institute 
Inc., Cary, NC) procedure, which takes into 
account possible correlation between the 
strata and clusters by which NHANES sam-
ples the population. Models were adjusted for 
relevant covariates instead of using NHANES 
sampling weights; this adjustment is regarded 
as a good compromise between efficiency and 
bias (Korn and Graubard 1991). 
Results
PFC concentrations were available for 2,094 
participants of the original subsample of 2,368 
people. PFOS levels were an order of mag-
nitude higher than the other PFCs, with a 
median of 19.9 µg/L serum compared with 
3.8 µg/L for PFOA. Similar to results in the 
same data set reported by Calafat et al. (2007), 
concentrations were higher in males compared 
with females, non-Hispanic whites compared 
with Mexican Americans and non-Hispanic 
blacks, and people of higher SES compared 
with those of lower SES. There were no strik-
ing concentration differences by age. The 
four PFCs were log-normally distributed and 
were moderately correlated with one another. 
PFOA and PFOS were most strongly corre-
lated, with a Spearman correlation coefficient 
of 0.65; PFHxS and PFNA were the least cor-
related at 0.12. Cholesterol, body weight, and 
insulin resistance outcomes varied with age, 
sex, and race/ethnicity and were correlated 
with one another in predictable ways. 
The number of participants in each analysis 
depended on the outcome and missing data. 
We present results for the cholesterol analyses 
among adults (20–80 years of age) in Tables 1 
and 2 and Figure 1. Supplemental Material, 
Figure 1 (doi:10.1289/ehp.0901165.S1), illus-
trates how we arrived at our final sample size, 
which does not include 12- to 19-year-olds 
(n = 640). Of adults with PFC and cholesterol 
measures (n = 1,310), we excluded the 20% 
who reported using cholesterol-lowering med-
ications and the 3% who were missing this 
variable. None of the covariates were missing 
in > 9% of people. Table 1 shows the distri-
bution of outcomes and PFC concentrations 
in this subpopulation, including PFC range 
and number of people in each quartile. In all 
cases, the PFC range in the fourth quartile is 
much wider than in the other three quartiles. 
Supplemental Material, Table 1 (doi:10.1289/
ehp.0901165.S1), provides information on 
the distribution of covariates.
Cholesterol. Figure 1 presents the adjusted 
associations between the four cholesterol mea-
sures and PFC serum concentrations for adults 
[Supplemental Material, Table 2 (doi:10.1289/
ehp.0901165.S1], presents crude associations). 
We omitted 12- to 19- year-olds because no 
data were available for two important covari-
ates, alcohol and smoking. See Supplemental 
Material, Table 3, for results stratified by age 
(including 12- to 19-year-olds) and sex. 
We found a positive association between 
TC and PFOS, PFOA, and PFNA concentra-
tions (Figure 1A). Adults in the highest PFOS 
quartile had TC levels 13.4 mg/dL (95% CI, 
3.8–23.0) higher than those in the lowest 
quartile. For PFOA, there was a 9.8-mg/dL 
(95% CI, –0.2 to 19.7) increase, and for PFNA, 
a 13.9-mg/dL (95% CI, 1.9–25.9) increase. 
TC appeared to increase linearly across the 
quartiles of PFC exposure, particularly for 
PFNA (p-value for trend = 0.04). When 
examined in age and sex subgroups, results 
were similar, with associations of greater mag-
nitude among persons 60–80 years of age. 
Associations were fewer and of smaller magni-
tude among 12- to 19-year-olds. In contrast, 
results for PFHxS indicated an inverse trend 
among adults (p-value for trend = 0.07). Those 
in the top PFHxS quartile had TC levels that 
were lower than those in the lowest quartile 
by –7.0 mg/dL (95% CI, –13.2 to –0.8). The 
same pattern held in the female age subgroups 
in particular. 
We found fewer consistent trends in the 
HDL analyses. We observed differences by 
age and sex; results for all adults (Figure 1B) 
may mask these findings in some cases [see 
Supplemental Material, Table 3 (doi:10.1289/
ehp.0901165.S1)]. PFOA and PFOS were 
associated with higher HDL in adolescent 
girls [effect estimates for the top quartile com-
pared with lowest of 4.3 (95% CI, 0.1 to 8.5) 
Figure 1. Differences in cholesterol levels, persons 20–80 years of age, with increasing quartile of PFC expo-
sure. (A) Change in TC (n = 860), (B) change in HDL (n = 860), (C) change in non-HDL (n = 860), and (D) change 
in LDL (n = 416). All models control for age, sex, race/ethnicity, SES, saturated fat intake, exercise, time in 
front of a TV or computer, alcohol consumption, smoking, and BMI. Median PFC levels (micrograms per 
liter) for each quartile are shown below/above the bar. Error bars represent SEs of the effect estimates (i.e., 
the difference between the quartile and the reference group), and p-values for trend are presented; 95% CIs 
for each effect estimate are available in Supplemental Material, Table 3 (doi:10.1289/ehp.0901165.S1). 
25
20
15
10
5
0
–5
–10
–15
25
20
15
10
5
0
–5
–10
–15
25
20
15
10
5
0
–5
–10
–15
4
3
2
1
0
–1
–2
–3
–4
C
h
a
n
g
e
 
i
n
 
T
C
 
(
m
g
/
d
L
)
C
h
a
n
g
e
 
i
n
 
n
o
n
-
H
D
L
 
(
m
g
/
d
L
)
C
h
a
n
g
e
 
i
n
 
H
D
L
 
(
m
g
/
d
L
)
C
h
a
n
g
e
 
i
n
 
L
D
L
 
(
m
g
/
d
L
)
p = 0.01
p = 0.02
p = 0.27 p = 0.84
p = 0.08
p = 0.78
p = 0.34 p = 0.31
p = 0.11
p = 0.10
PFOS
PFOS PFOS
PFOS
PFOA
PFOA PFOA
PFOA
PFNA
PFNA
Quartile of PFC serum level Quartile of PFC serum level
Quartile of PFC serum level Quartile of PFC serum level
PFNA
PFNA
PFHxS
PFHxS PFHxS
PFHxS
p = 0.07
p = 0.05
p = 0.04
Q1
Q2
Q3
Q4
p = 0.04
p = 0.04
p = 0.07
9.91 72 .1 1.02 .0 3.40 .4
0.8
9.91 72 43 8
9.91 72 43 8
1.52.4
2.13 .4 0.4 2.4
2.4
0.81 .5 5.3
0.81 .5 5.3
0.71.0 2.0 4.66 .9
2.13 .4 0.40 .71.02 .0 4.66 .9
5.3
0.81 .52.45 .3
0.7
1.02 .0 0.40.7
4.66 .9
2.13 .44.66 .9
24 38
9.91 72 43 8Nelson et al.
200  v o l u m e  118 | n u m b e r 2 | February 2010  •  Environmental Health Perspectives
and 3.7 (95% CI, –0.5 to 7.9), respectively], 
with some evidence of the opposite in the 
older age group [in males 60–80 years of age, 
effect estimate for the top PFOA quartile 
compared with the lowest of –8.7 (95% CI, 
–16.3 to –1.1)]. No meaningful associations 
were observed between PFNA and PFHxS 
concentration and HDL. 
Results for non-HDL were similar to 
those for TC, as would be expected, because 
the non-HDL fraction makes up 70–80% 
of TC (Figure 1C). The magnitude of effect 
increased slightly for PFNA and PFHxS. LDL 
results (Figure 1D) should mirror those for 
non-HDL; however, the sample size for LDL 
analyses was half as large. We found a some-
what similar pattern for PFNA and PFHxS, 
but no association with PFOA and PFOS 
concentration. 
We repeated all cholesterol models and 
adjusted for albumin. Results were substan-
tively the same as those presented above (data 
not shown). Results were similar as well in 
models that considered PFC concentration 
as a continuous predictor (Table 2). PFOS, 
PFOA, and PFNA were all positively associ-
ated with TC and non-HDL (effect estimates 
were statistically significant for PFOS and 
PFOA). The opposite was seen for PFHxS, 
which was negatively associated with TC, non-
HDL, and LDL. 
In addition, we performed several sensitiv-
ity analyses that also had no qualitative effect 
on results from the quartile analysis: the inclu-
sion of adults missing data on use of choles-
terol-lowering medication, the inclusion of all 
adults (even those who reported taking medica-
tions), the exclusion of points identified as out-
liers in the continuous models from Table 2, 
and use of NHANES sampling weights. 
Body weight. We found fewer meaningful 
associations between body weight and PFC 
concentrations [see Supplemental Material, 
Table 3 (doi:10.1289/ehp.0901165.S1)]. The 
strongest effects were seen with PFOS among 
males. In males 12–19 and 20–59 years of age, 
BMI decreased with increasing PFOS exposure. 
Teenage boys in the highest PFOS quartile had 
BMIs that were 2.8 points (95% CI, –4.1 to 
–1.4) lower than those in the lowest quartile 
(p-value for trend = 0.004). In men 60–80 
years of age, on the other hand, increasing 
PFOS exposure was associated with increased 
BMI [effect estimate for the top quartile com-
pared with lowest of 1.6 (95% CI, 0.14–3.0)]. 
We did not see evidence of a relationship in 
the female age groups. Results for the other 
PFCs were less consistent, and those for WC 
were similar to BMI. 
HOMA. On the whole, we found no 
association between PFC concentrations and 
HOMA. Although there were isolated sugges-
tive trends, such as a significant positive trend 
with PFNA in adult females and a negative one 
with PFHxS in adolescent females, effects were 
not consistent [see Supplemental Material, 
Table 3 (doi:10.1289/ehp.0901165.S1)].
Discussion
This exploratory study examined associations 
between serum concentrations of four PFCs 
and cholesterol levels, body size, and insu-
lin resistance in a sample of the general U.S. 
population. Most striking were the findings 
for TC and non-HDL. These outcomes were 
positively associated with PFOS, PFOA, and 
PFNA and negatively associated with PFHxS 
after controlling for numerous covariates in 
categorical and continuous models. The LDL 
analyses were more limited by study size, but 
revealed similar trends for PFHxS and PFNA, 
although of less consistency and magnitude. 
No strong trends emerged in the HDL anal-
yses. These results suggest that exposure to 
background levels of certain PFCs may exert 
effects on the non-HDL fraction of choles-
terol. We did not find consistent associations 
between PFCs and BMI, WC, or HOMA. 
Previous studies in humans. Studies of 
the association between cholesterol levels and 
PFCs are found primarily in the occupational 
health literature. Although results are not 
entirely consistent, the general trend is one 
of positive associations between PFOA con-
centration and cholesterol levels. Results for 
PFOS are less clear, as it has been less stud-
ied. Sakr et al. (2007a, 2007b) studied a large 
cohort of DuPont workers (n = 454 for a lon-
gitudinal study and 1,025 for a cross-sectional 
study). In both, PFOA was positively associ-
ated with TC but not with HDL. A positive 
association was observed with LDL in the 
cross-sectional study only. When restricted to 
those not taking cholesterol-lowering medica-
tions, the magnitude of effect in the cross-
sectional study increased. A study of a smaller 
group of Italian workers (n = 53), which 
included a substudy excluding those being 
treated for hyperlipidemia, found a similar 
positive association between TC and PFOA 
(Costa et al. 2009). Findings from studies 
of workers at different 3M Company loca-
tions are more mixed. The most recent study 
conducted by Olsen and Zobel (2007) did 
not find evidence of an association between 
serum PFOA and TC or LDL among 506 
employees at three facilities. An earlier study 
of the same workers at two of those locations, 
which did not adjust for use of cholesterol-
lowering medications, found a positive asso-
ciation between serum PFOS and PFOA and 
TC in a cross-sectional analysis (n = 421) and 
PFOA in a longitudinal analysis (n = 174) 
(Olsen et al. 2003). 
Exposure levels in these workers are 
much higher than in NHANES partici-
pants. Median serum concentrations in the 
3M cohort were 1,100 µg/L for PFOA and 
720 µg/L for PFOS (Olsen and Zobel 2007). 
The mean PFOA level was 4,300 µg/L in 
the DuPont studies (Sakr et al. 2007a); the 
median was 3,890 µg/L in 2007 measure-
ments from the Italian cohort (Costa et al. 
2009). In comparison, median serum concen-
trations in NHANES were 4 and 20 µg/L for 
PFOA and PFOS, respectively.
Two studies have also been conducted 
on PFCs and cholesterol outcomes in com-
munities surrounding a DuPont plant that 
have much higher PFOA exposures than the 
general population. Emmett et al. (2006) 
examined PFOA concentrations among 371 
residents of a water district area bordering the 
plant. Although the study found no associa-
tion between PFOA and TC, the analyses nei-
ther controlled for possible confounders nor 
excluded people on cholesterol-lowering medi-
cations. The C8 Health Project, a much larger 
study conducted in relation to a legal case, has 
released preliminary, non-peer-reviewed find-
ings from its analysis of 46,294 people living 
in six water districts near the plant (C8 Science 
Panel 2008). The study, which excluded those 
on cholesterol medications and controlled for 
confounding, found significant positive asso-
ciations between PFOA and PFOS concentra-
tions and TC and LDL.
A recent study using NHANES data 
examined the relationship between PFCs 
and components of the metabolic syndrome 
in 1999–2000 and 2003–2004 participants 
(Lin et al. 2009). It is difficult to compare 
our study with these results, as the authors 
examined an additional 2 years of data, did 
not report results for TC, non-HDL, or LDL, 
and conducted logistic regression analyses for 
two of the outcomes. They found a signifi-
cant positive association between HOMA and 
PFOS concentrations in adults, similar to the 
direction of association we observed (although, 
in our study, the trend did not come close 
to statistical significance). PFNA concentra-
tions were found to have a protective effect on 
the odds of having low HDL in adolescents 
and adults, with the opposite seen for PFOS 
in adults. Our study did not observe these 
relationships with HDL as a continuous out-
come. Finally, the authors found that higher 
PFHxS, PFOA, and PFOS concentrations 
in adolescents were associated with decreased 
WC, findings we also observed for PFOS. 
There have been few studies of non-
developmental PFC exposure and body size. 
A cross-sectional study of 3M workers found 
BMI to be slightly higher in the highest cat-
egory of PFOA exposure, although there was 
no adjustment for confounding (Olsen et al. 
1998). Another study found that mothers 
who were overweight or obese before preg-
nancy had higher plasma levels of PFOS and 
PFOA (Fei et al. 2007), and a third observed 
higher PFOS and PFOA levels in cord blood PFCs and cholesterol in the general U.S. population
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of both overweight and underweight women 
(Apelberg et al. 2007).
Previous studies in animals. Unlike in 
humans, studies in rodents found consistent 
inverse associations between cholesterol levels 
and exposure to PFOS and PFOA, although 
doses administered were much higher than 
typical human exposure levels (Martin et al. 
2007; Thibodeaux et al. 2003). In cynomolgus 
monkeys, decreased TC was reported as the 
earliest reliable measure of a clinical response 
after PFOS exposure (Seacat et al. 2002). This 
hypolipidemic effect in primates has not been 
seen with PFOA exposure, however (Butenhoff 
et al. 2002). We are not aware of similar ani-
mal studies of PFNA or PFHxS exposure. 
Weight loss has also been a common find-
ing in high-dose animal studies of PFOS and 
PFOA (Seacat et al. 2002; Thibodeaux et al. 
2003). A recent study in mice of PFOA expo-
sure and body weight tested a wide range of 
doses and looked at both adult and develop-
mental exposure (Hines et al. 2009). Exposure 
during adulthood was not associated with 
later-life body weight effects, whereas low-
dose developmental exposure led to greater 
weight in adulthood and increased serum 
leptin and insulin levels. Animals exposed to 
higher doses of PFOA, on the other hand, 
had decreased weight. 
Possible modes of action. The hypothesized 
mode of action for the hypolipidemic effects 
of PFCs in animals is through activation of 
PPARα, the PPAR isoform involved in lipid 
homeostasis and peroxisome proliferation 
(Wolf et al. 2008). Multiple in vitro studies 
have shown PFCs to be PPARα ligands in 
rodent and human cells (Vanden Heuvel et al. 
2006; Wolf et al. 2008). Activation is greater 
as carbon backbone length increases, and car-
boxylates (PFOA and PFNA) have higher acti-
vation than sulfonates (PFOS and PFHxS). 
PFCs may also indirectly activate PPARα by 
interacting with fatty acid–binding proteins 
(Luebker et al. 2002). PPARα ligands, such as 
the fibrate class of cholesterol-lowering medi-
cations, inhibit secretion of cholesterol from 
the liver, reducing cholesterol in the serum 
(Kennedy et al. 2004). PPARγ is another 
PPAR isoform more closely involved in adi-
pogenesis (Grun and Blumberg 2009). Some 
PFCs weakly activate PPARγ in certain human 
cell lines (Vanden Heuvel et al. 2006). 
PPAR-independent mechanisms could be 
involved as well. PFOS and PFOA have been 
shown to interact with other nuclear receptors, 
including the constitutive activated receptor 
and pregnane X receptor (Ren et al. 2009). 
Interspecies differences may partly explain 
the inconsistent cholesterol findings between 
animal and human studies. Humans are 
less sensitive to PPARα–related effects than 
rodents, with approximately 10-fold lower 
expression of PPARα in liver compared with 
mice (Tilton et al. 2008). There are also major 
differences in PFC half-life and metabolism. 
Whereas the half-life of PFOA in human 
serum is estimated to be 3.8 years, in mice it 
is around 18 days (Lau et al. 2007). Finally, 
rodents and humans have different plasma 
lipid profiles, with HDL, rather than LDL, 
predominating in rodents (Lima et al. 1998). 
Implications for the current study. The 
positive associations we observed between 
serum concentrations of PFOS, PFOA, and 
PFNA and TC are consistent with much of 
the occupational health literature regarding 
PFOA, even though serum concentrations in 
studies of workers were at least one order of 
magnitude higher than in NHANES. Our 
findings for PFOA and PFOS are also consis-
tent with emerging results from the very large 
C8 Health Study cohort. Although hyper-
lipidemia is not consistent with the animal lit-
erature, this may be explained by differences 
between species and/or doses studied. 
The strongest, most consistent cholesterol 
results were seen for PFNA, despite lower 
serum concentrations in the NHANES popu-
lation. This is biologically plausible, given that 
PFC toxicity seems to increase with carbon 
chain length. Correlation with PFOS and/or 
PFOA could also partly explain the results, 
though PFNA is only moderately correlated 
with them (r = 0.5). Very few studies have 
been conducted on the possible health effects 
of PFNA. Another notable finding was that 
PFHxS consistently acted in the opposite direc-
tion of the other PFCs in the cholesterol analy-
ses. Of the compounds studied, PFHxS has the 
shortest carbon chain and the longest estimated 
half-life. This differential effect of PFHxS is not 
found in the literature; more research is needed 
to assess possible mechanisms of PFHxS action 
that may differ from longer-chain PFCs. 
The lack of consistent findings regarding 
body size is not entirely surprising. Although 
interesting findings have been published 
recently on developmental exposures in both 
humans and animals (Fei et al. 2007, Hines 
et al. 2009), adult exposures appear to be less 
of a concern. Effects on insulin resistance have 
been studied very little.
Limitations and strengths. Our study has 
a number of limitations that make it explora-
tory in nature. The NHANES data are cross- 
sectional, limiting our ability to rule out reverse 
causality. It is possible that PFCs behave differ-
ently in the bodies of people who have higher 
cholesterol levels. In addition, the hypothesis 
has been raised that the positive associations 
observed here and in occupational health stud-
ies between PFCs and TC may be due to the 
fact that PFCs bind to β-lipoproteins and albu-
min in the blood (Olsen and Zobel 2007). 
Han et al. (2003) concluded that, in human 
and rat serum, more than 90% of PFOA 
would be bound to albumin. The only report 
regarding PFC binding to β-lipoproteins is a 
short, non-peer-reviewed document found in a 
U.S. Environmental Protection Agency docket 
that found that PFOS, PFOA, and PFHxS 
all bind tightly to albumin, but that differ-
ences exist in binding to β-lipoproteins, with 
96% of PFOS binding compared with 64% of 
PFHxS and 40% of PFOA (Kerstner-Wood 
et al. 2003). The authors conclude that the data 
show “that albumin is by far the largest single 
protein binder for three of the four compounds 
tested. . . . The fourth compound, PFOS, was 
found to be highly bound by both albumin 
and β-lipoproteins.”
To address these concerns, we showed 
that controlling for serum albumin did not 
affect associations between serum PFCs and 
cholesterol. Confounding by PFC binding 
to β-lipoproteins is still an issue, although 
we would expect this to be most striking for 
PFOS, which binds most highly. The fact that 
we see similar results for PFOS, PFOA, and 
PFNA is somewhat reassuring, as is the fact 
that we see an inverse association with PFHxS. 
If major confounding by β-lipoprotein binding 
were occurring, we would expect to see a stron-
ger positive association between cholesterol and 
PFHxS than PFOA. Our results for PFOA are 
also consistent with occupational studies that 
were able to model longitudinal data.
Additional limitations of our study include 
the fact that we have only one measurement of 
PFC and cholesterol concentrations. Because 
PFCs have relatively long half-lives, we can 
be fairly confident that blood concentrations 
reflect longer-term exposure, but cholesterol 
levels have significant variability, and multiple 
measures are ideal (Tietz et al. 2006). If this 
measurement error is random and not related 
to PFC level, which seems likely, it should 
not bias the estimate, but rather increase the 
standard deviation. There is also the potential 
for residual confounding by diet or other fac-
tors. Because NHANES measures different 
classes of environmental chemicals in different 
subsamples of the population, we were unable 
to consider coexposure to other chemicals sus-
pected to disrupt weight and lipid regulation. 
Despite these limitations, our study has a 
number of strengths. It has a relatively large 
sample size and the ability to account for key 
covariates such as alcohol consumption and 
use of cholesterol-lowering medications. The 
large population also allows for consideration 
of modification by age and sex. In addition to 
PFOA and PFOS, we examined PFNA and 
PFHxS, compounds that have received less 
scientific attention but appear important to 
study further. 
Conclusion
Although these results are based on cross- 
sectional data and are exploratory, they are con-
sistent with much of the human epidemiologic Nelson et al.
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literature and indicate that PFCs may be exert-
ing an effect on cholesterol metabolism at 
environmentally relevant exposures. Our study 
affirms the importance of investigating PFCs 
other than PFOS and PFOA, particularly as 
industrial uses of PFOS and PFOA decline 
and other PFCs are substituted. PFNA may 
be of particular concern, as the chemical was 
detected in 98% of NHANES participants 
and serum concentrations rose between the 
time periods of 1999–2000 and 2003–2004 
(Calafat et al. 2007). In some cases, PFNA had 
a greater magnitude of effect on cholesterol 
levels than PFOS and PFOA. 
Although this study does not demonstrate 
a causal association between PFC exposure 
and serum cholesterol levels, it provides clues 
about where to focus future epidemiologic 
and toxicology research. In particular, addi-
tional studies are needed to shed light on 
explanations for the opposite associations with 
cholesterol observed for PFHxS compared 
with the other PFCs studied and on the rela-
tionship between PFC binding to proteins in 
the blood, particularly beta-lipoproteins, and 
cholesterol levels. Despite its limitations, this 
study contributes to the literature suggesting 
that PFC exposure may disrupt cholesterol 
metabolism or homeostasis in humans.
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